American Journal of Ophthalmology
Volume 142, Issue 5 , Pages 777-787.e2 , November 2006

Cannulation of the Suprachoroidal Space: A Novel Drug Delivery Methodology to the Posterior Segment

  • Timothy W. Olsen, MD

      Affiliations

    • University of Minnesota, Department of Ophthalmology, Minneapolis, Minnesota
    • Corresponding Author InformationInquiries to Timothy W. Olsen, MD, University of Minnesota Department of Ophthalmology, MMC 493, 420 Delaware Street SE, Minneapolis, MN 55455-0501
    • ,
  • Xiao Feng, MD

      Affiliations

    • University of Minnesota, Department of Ophthalmology, Minneapolis, Minnesota
    • ,
  • Kathy Wabner, BA

      Affiliations

    • University of Minnesota, Department of Ophthalmology, Minneapolis, Minnesota
    • ,
  • Stanley R. Conston, BS

      Affiliations

    • iScience Surgical Corp, Menlo Park, California
    • ,
  • David H. Sierra, PhD

      Affiliations

    • iScience Surgical Corp, Menlo Park, California
    • ,
  • David V. Folden, MD

      Affiliations

    • University of Minnesota, Department of Ophthalmology, Minneapolis, Minnesota
    • ,
  • Morton E. Smith, MD

      Affiliations

    • Washington University, St Louis, Missouri
    • ,
  • J. Douglas Cameron, MD

      Affiliations

    • Mayo Clinic, Department of Ophthalmology, Rochester, Minnesota

,Accepted 25 May 2006.

References 

  1. Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci. 2000;41:961–964
  2. Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability (Effects of age, cryotherapy, transscleral diode laser, and surgical thinning). Invest Ophthalmol Vis Sci. 1995;36:1893–1903
  3. Olsen TW, Aaberg SY, Geroski DH, Edelhauser HF. Human sclera: thickness and surface area. Am J Ophthalmol. 1998;125:237–241
  4. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina. 2004;24:S3–S19
  5. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch Ophthalmol. 1994;112:1531–1539
  6. Jaffe GJ, McCallum RM, Branchaud B, et al. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology. 2005;112:1192–1198
  7. Jaffe GJ, Yang CH, Guo H, et al. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci. 2000;41:3569–3575
  8. Martin DF, Ferris FL, Parks DJ, et al. Ganciclovir implant exchange: timing, surgical procedure, and complications. Arch Ophthalmol. 1997;115:1389–1394
  9. Guyer D, Schachat A, Green R. The choroid: structural considerations. In:  Ryan S editors. Retina. 4th ed. St Louis, Missouri: CV Mosby; 2006;p. 33–42
  10. Krohn J, Bertelsen T. Corrosion casts of the suprachoroidal space and uveoscleral drainage routes in the human eye. Acta Ophthalmol Scand. 1997;75:32–35
  11. Krohn J, Bertelsen T. Corrosion casts of the suprachoroidal space and uveoscleral drainage routes in the pig eye. Acta Ophthalmol Scand. 1997;75:28–31
  12. Krohn J, Bertelsen T. Light microscopy of uveoscleral drainage routes after gelatine injections into the suprachoroidal space. Acta Ophthalmol Scand. 1998;76:521–527
  13. Einmahl S, Savoldelli M, D’Hermies F, et al. Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye. Invest Ophthalmol Vis Sci. 2002;43:1533–1539
  14. Poole TA, Sudarsky RD. Suprachoroidal implantation for the treatment of retinal detachment. Ophthalmology. 1986;93:1408–1412
  15. Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol. 1982;93:415–417
  16. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–2816
  17. Smithen LM, Spaide RF. Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Am J Ophthalmol. 2004;138:884–885
  18. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2003;110:1517–1525
  19. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005;112:301–304
  20. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization. Retina. 2005;25:685–690
  21. Ohji M, Tano Y. Vitreoretinal surgery with slit-lamp illumination combined with a wide-angle-viewing contact lens. Am J Ophthalmol. 2004;137:955–956
  22. Pagot V, Mathis A, Heldenbergh O, et al. Surgery of retinal detachment of patients with pseudophakia using the panfunduscope. J Fr Ophtalmol. 1992;15:587–591
  23. Olsen TW, Sanderson S, Feng X, Hubbard WC. Porcine sclera: thickness and surface area. Invest Ophthalmol Vis Sci. 2002;43:2529–2532
  24. Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina. 2005;25:556–560
  25. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681–686

 Supplemental Video available at AJO.com.Supported in part by grants from the iScience Surgical Corp, Minnesota Lions Macular Degeneration Center, Minneapolis, Minnesota; University of Minnesota Vision Foundation, Minneapolis, Minnesota; and an unrestricted research grant from Research to Prevent Blindness, New York, New York.

PII: S0002-9394(06)00700-8

doi: 10.1016/j.ajo.2006.05.045

American Journal of Ophthalmology
Volume 142, Issue 5 , Pages 777-787.e2 , November 2006

Article Tools

* Image Usage & Resolution